fda warning compounding semaglutide october 2025 is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Demand for Unapproved Weight-Loss Drug

PubMed laboratory research record [PMID: 19827991] PubMed record related to this compound for laboratory literature review

The FDA has only approved six weight loss drugs, including: Bupropion-naltrexone (Contrave) Liraglutide (Saxenda) Orlistat (Xenical, Alli) Phentermine-topiramate (Qsymia) Semaglutide (Wegovy) Setmelanotide (Imcivree) Currently, the choice of weight loss drugs remains very limited and is divided into two main categories: pancreatic lipase inhibitors and appetite suppressants that act on the central nervous system

Document your injection site in a notebook or phone reminder to ensure you rotate properly each week and never inject into areas of existing lumps or scar tissue

ILLEGAL SALES Few realise that a doctors prescription is required, as these drugs can cause side effects such as nausea, gallstone disease and eye conditions

Important: Wegovy is NOT FDA-approved for sleep apneathat approval went to Zepbound (tirzepatide) in December 2024

Li G, Huang X